UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2208-6
Program Prior Authorization/Medical Necessity
Medication Caplyta® (lumateperone)
P&T Approval Date 6/2020, 7/2021, 3/2022, 6/2022, 11/2023, 11/2024
Effective Date 2/1/2025
1. Background:
Caplyta is FDA approved for the treatment of schizophrenia and for depressive episodes associated
with bipolar I or II disorder as monotherapy and as adjunctive therapy with lithium or valproate in
adults. This program requires a member to try three atypical antipsychotics for schizophrenia or two
atypical antipsychotics for bipolar depression before providing coverage for Caplyta.
2. Coverage Criteriaa:
A. Initial Authorization
1. Caplyta will be approved based on ONE of the following criteria:
a. BOTH of the following:
1) Diagnosis of schizophrenia
-AND-
2) History of failure, contraindication, or intolerance to three of the following (please
document drug, date and duration of trial):
(a) aripiprazole (generic Abilify)
(b) olanzapine (generic Zyprexa)
(c) quetiapine IR or ER (generic Seroquel or Seroquel XR)
(d) risperidone (generic Risperdal)
(e) ziprasidone (generic Geodon)
-OR-
b. BOTH of the following:
1) Diagnosis of depressive episodes associated with bipolar I or II disorder (bipolar
depression)
-AND-
© 2024 UnitedHealthcare Services, Inc.
1
2) History of failure, contraindication, or intolerance to both of the following (please
document date and duration of trial):
(a) olanzapine (generic Zyprexa) in combination with an SSRI (e.g. fluoxetine)
(b) quetiapine IR or ER (generic Seroquel or Seroquel XR)
-OR-
c. Treatment with Caplyta was initiated at a recent behavioral inpatient admission
(discharge within the past 3 months) and the member is currently stable on therapy.
(Please document date of discharge from inpatient admission).
-OR-
d. Member is new to the plan and currently stabilized on Caplyta (as evidenced by
coverage effective date of less than or equal to 120 days)
Authorization will be issued for 12 months.
B. Reauthorization
1. Caplyta will be approved for continuation of therapy based on the following criterion:
a. Documentation of a positive clinical response to therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits and Prior Authorization/Notification may also be in place.
4. References:
1. Caplyta [package insert]. New York, NY: Intra-Cellular Therapies, Inc. June 2023.
2. American Psychiatric Association. Practice Guideline for the Treatment of Patients with
Schizophrenia Third Edition. Available at:
https://psychiatryonline.org/doi/10.1176/appi.books.9780890424841
3. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Bipolar
Disorder Second Edition. Available at:
https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar.pdf
© 2024 UnitedHealthcare Services, Inc.
2
Program Prior Authorization/Medical Necessity - Caplyta (lumateperone)
Change Control
6/2020 New program.
7/2021 Annual review. Updated references and added continuation of therapy
coverage criteria.
3/2022 Updated to include coverage for depressive episodes associated with
bipolar disorder due to new labeling.
6/2022 Modified criteria for bipolar depression. Updated references.
11/2023 Updated references.
11/2024 Annual review with no changes.
© 2024 UnitedHealthcare Services, Inc.
3